- The paper demonstrates that the novel To2GyConstraints method overcomes limitations of BED/EQD2 by accurately converting hypofractionated doses using adaptive LQ and LQ-L models.
- The technique provides spatially resolved dose conversion that maintains clinical realism in low-dose and peripheral regions critical for OAR assessment.
- Validation in a prostate cancer plan confirms that the method enhances cumulative dose evaluation and supports improved treatment planning.
Voxel-Based Conversion of Hypofractionated Radiotherapy Dose Distributions to 2 Gy-Equivalent OAR Constraints: Technical Summary and Implications
Introduction
The manuscript addresses a critical challenge in clinical radiotherapy: the need for accurate and biologically consistent conversion of hypofractionated dose distributions to an equivalent normofractionated (2 Gy per fraction) scheme, specifically with respect to organ-at-risk (OAR) constraints. Standard approaches, including biologically effective dose (BED) and equivalent dose in 2 Gy fractions (EQD2) voxelwise conversion, present substantial limitations. These include poor applicability in low-dose regions for OAR evaluation, lack of clinical realism, and inaccuracy for doses per fraction above the validity limit of the linear-quadratic (LQ) model (7.5 Gy). The authors propose and validate a new voxel-based methodology—To2GyConstraints—that generalizes beyond current methods by generating 2 Gy-equivalent dose constraints tailored for OAR analysis in hypofractionated regimens.
Methodological Framework
The To2GyConstraints converter operates on the principle of individualized per-voxel dose conversion using established radiobiological models. The approach dynamically selects between the LQ and the linear-quadratic-linear (LQ-L) models based on dose per fraction: LQ for d≤7.5 Gy and LQ-L for higher doses. Conversion is further refined by defining a per-voxel threshold, set as the mean between the prescribed hypofractionated fraction dose and 2 Gy. For voxels below this threshold, an equivalent number of fractions is calculated and a generalized EQDx conversion is applied. Voxels above the threshold are converted via classic EQD2.
This method specifically improves upon prior approaches by:
- Reflecting the spatial heterogeneity inherent to clinical dose distributions, particularly correct handling of voxels outside the planning target volume (PTV) and in low-dose regions, which are pivotal for valid OAR constraint assessment.
- Mitigating the radiobiologically inconsistent scenario presented by EQD2, where cumulative normofractionated dose in OAR voxels may fall below the actually prescribed hypofractionated dose.
- Providing output dose distributions importable into standard treatment planning systems for further analysis via dose-volume histograms (DVHs).
For validation, the method was applied to a 60 Gy in 20 fractions (hypofractionated) prostate cancer plan, comparing BED, EQD2, and To2GyConstraints conversions across critical voxels situated within and near the PTV.
Numerical Results and Analysis
The test case revealed several key findings:
- In the PTV, BED conversion produced values (~120–189 Gy) grossly discordant with clinically accepted prescription doses, undermining its suitability for OAR constraint comparison.
- For peripheral OAR voxels (e.g., those on the 50% isodose), classic EQD2 conversion underestimates the effective dose upon mapping to a 2 Gy per fraction context (e.g., 30 Gy hypofractionated mapping to only 28 Gy in EQD2), a result that is not physically or radiobiologically justified.
- To2GyConstraints conversion yielded values that maintained clinical realism and consistency, ensuring that the converted OAR doses did not underestimate OAR exposure in the normofractionation-equivalent scenario.
The authors emphasize that, in the prostate setting (very low α/β for tumor), hypofractionation enables sparing of normal tissue even when OAR regions are dose-overlapping with the PTV. This differential is preserved by To2GyConstraints but is masked or misrepresented by classical BED/EQD2 conversions.
Theoretical and Practical Implications
The proposed methodology has several immediate and far-reaching implications:
- It enables direct comparison and summation of normofractionated-equivalent plans, supporting reirradiation and cumulative toxicity assessments spanning multiple treatments with non-uniform fractionation schedules.
- The formalism underlines the necessity of spatially resolved, model-adaptive dose conversion in mixed-fractionation radiotherapy—a requirement not addressed by bulk or single-threshold methods.
- Clinically, the work supports the adoption and optimization of hypofractionated schemes in prostate cancer and potentially other sites with low α/β tumors and OAR overlap scenarios. The generalizability to other disease sites will require multi-institutional and multi-indication validation as called for by the authors.
The analysis also indicates that established clinical protocols for OAR sparing may need to be recalibrated when hypofractionation is used, provided that equivalent—or superior—sparing is achievable and verifiable through voxel-based dose conversion techniques such as the one described.
Future Directions
The necessity for multi-site, multi-cohort validation is emphasized, as are the prospects of integrating this methodology with AI-driven or adaptive radiotherapy workflows. Such integration could leverage more robust biological models, patient-specific α/β estimation, and deep learning to optimize both tumor control and OAR protection across heterogeneous clinical scenarios. Additionally, this voxel-based approach sets a formal precedent for more accurate retrospective toxicity and outcome modeling in the era of personalized, fractionation-adaptive radiotherapy.
Conclusion
The work presents a robust, biologically justified solution to the challenge of hypofractionation-to-normofractionation dose conversion for OAR constraints in radiotherapy planning. The To2GyConstraints method corrects major conceptual and practical limitations in current conversion tools, particularly in low-dose, OAR-critical regions. While further clinical validation is required—especially across disease sites and institutional protocols—the approach substantially advances the standardization and accuracy of cumulative dose assessment in complex, multi-fractionation radiotherapy paradigms.
